Bibliography
- EURORDIS is a non-governmental patient-driven alliance of patient organisations representing 544 rare disease patient organisations in 49 countries. Available from: http://www.eurordis.org/
- Liu BC, He L, He G, He Y. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy. J Public Health Policy 2010;31(4):407-20
- Franco P. Orphan drugs: the regulatory environment. Drug Discov Today 2013;18(3-4):163-172
- Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities.
- Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts ‘similar medicinal product' and ‘clinical superiority'. Official Journal of the European Communities
- Guideline on the format and content of applications for designation as orphan medicinal products and on the transfer of designations from one sponsor to another, 9 July 2007. Brussels, 9 July 2007 ENTR/6283/00 Rev 3. European Commission Enterprise Directorate-General
- http://ec.europa.eu/health/documents/community-register/html/orphreg.htm
- Regnstrom J, Koenig F, Aronsson B, Factors associated with success of marketing authorisations for pharmaceutical drugs submitted to the European Medicines Agency. Eur J Clin Pharmacol 2010;66:39-48
- Guideline on aspects of the application of Article 8(1) and (3) of Regulation (EC) No 141/2000: Assessing similarity of medicinal products versus authorised orphan medicinal products benefiting from market exclusivity and applying derogations from that market exclusivity. Commission of the European Communities. Brussels, 19.9.2008 C(2008) 4077 final
- http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm
- http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/OrphanDrugAct/default.htm
- http://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan_drug.html
- Braun MM, Farag-El-Massah S, Xu K, Cote TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010;9(7):519-22
- COMP and the EMA. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov 2011;10(5):341-9
- Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010;9(12):921-9